Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Prescription Medication
Pharmalot

AbbVie and J&J reverse course on a price hike in face of criticism

By Ed Silverman

Swiss Attorney General
Pharmalot

Swiss prosecutor eyes Novartis deal with Cohen, but no criminal probe is underway — for now

By Ed Silverman

Gottlieb Generic Drugs
Politics

FDA to name companies accused of hindering generic drug development

By Ike Swetlitz

Pharmalot

Pharmalittle: Connecticut moves closer to pricing law; Philippines starts criminal probe into dengue vaccine

By Ed Silverman

The Pharmalot View

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

By Ed Silverman

Alex Azar
Politics

From drug ads to Medicare moves, 5 policy takeaways from Trump’s drug pricing speech

By Ike Swetlitz, Erin Mershon, and Lev Facher

Donald Trump Alex Azar drug prices speech
Business

Trump promised to bring pharma to justice. His speech sent drug stocks soaring

By Adam Feuerstein and Damian Garde

Trump drug prices
Politics

Trump denounces ‘middlemen,’ largely spares pharma in drug pricing speech

By Erin Mershon and Ike Swetlitz

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Ron Wyden
Pharmalot

Democratic senator opens probe into Novartis over its dealings with Trump’s attorney

By Ed Silverman

Pharmalot

Pharmalittle: White House promises ‘comprehensive’ drug plan; judge overseeing opioid cases still pushes for settlement

By Ed Silverman

Trump Drug Pricing
Politics

White House trumpeting drug plan as most far-reaching ‘of any president’

By Erin Mershon

Antibiotic Resistance
Pharmalot

Tennessee becomes the second state to pass a law allowing pharma to promote off-label uses

By Ed Silverman

Joe Jimenez and Vasant Narasimhan
Exclusive

‘Not a good day for Novartis’: CEO tries to reassure employees amid fury over payments to Trump’s lawyer

By Ed Silverman

Pharmalot

Pharmalittle: Roche suffers a setback in a cancer trial; Trump wants to shift Medicare B drugs to Part D

By Ed Silverman

Business

Eli Lilly acquires small biotech for $1.6 billion to strengthen cancer immunotherapy pipeline

By Adam Feuerstein

Politics

Novartis paid Trump’s lawyer’s firm far more than any of its actual lobbyists

By Erin Mershon

Exclusive

Trump’s lawyer pitched himself as a fixer to Novartis and got paid $1.2 million

By Ed Silverman

Novartis Window
Pharma

Untangling Trump’s lawyer’s ties to Novartis: Here are 6 unanswered questions

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Rep. Peter Welch
Pharmalot

Lawmakers introduce bill to fine drug makers for incorrect Medicaid classifications

By Ed Silverman

Patrick Morrisey
Politics

A contentious West Virginia Senate race pits two candidates with close ties to pharma

By Lev Facher

Pharmalot

Pharmalittle: Jazz pays $57 million to resolve probe into charity support; EpiPen shortages mount in the U.S.

By Ed Silverman

Novartis campus
Pharmalot

Novartis paid nearly $400,000 to a shell company controlled by Trump’s attorney

By Ed Silverman

Pharmalot
Pharmalot

As Fresenius accuses Akorn of ‘blatant fraud,’ FDA cites complaints of ‘black gunk’ in Akorn products

By Ed Silverman

Andy Plump Takeda
Pharmalot

Takeda R&D chief says the Shire deal will accelerate plans by three to five years

By Ed Silverman

Pharmalot

With a push from pharma, U.S. Trade Rep pressure on Colombia starts to take hold

By Ed Silverman

Pharmalot

Pharmalittle: Takeda finally makes a deal for Shire; Congress probes insulin pricing today

By Ed Silverman

Pharmalot

John Arnold: ‘These pricing trends can’t continue without bankrupting … the system’

By Ed Silverman

Seema Verma
Pharma

CMS chief criticizes Medicare drug payments for ‘perverse’ incentives

By Erin Mershon

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.